Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1

被引:38
作者
Hedley, Benjamin D. [1 ,2 ]
Welch, Danny R. [3 ,4 ]
Allan, Alison L. [1 ,5 ,6 ]
Al-Katib, Waleed [1 ]
Dales, David W. [1 ]
Postenka, Carl O. [1 ]
Casey, Graham [7 ]
MacDonald, Ian C. [2 ,5 ]
Chambers, Ann F. [1 ,2 ,5 ,8 ]
机构
[1] London Hlth Sci Ctr, London Reg Canc Program, London, ON N6A 4L6, Canada
[2] Univ Western Ontario, Dept Med Biophys, Schulich Sch Med & Dent, London, ON, Canada
[3] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA
[4] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA
[5] Univ Western Ontario, Dept Oncol, Schulich Sch Med & Dent, London, ON, Canada
[6] Univ Western Ontario, Dept Anat & Cell Biol, Schulich Sch Med & Dent, London, ON, Canada
[7] Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA
[8] Univ Western Ontario, Dept Pathol, Schulich Sch Med & Dent, London, ON, Canada
关键词
breast cancer; BRMS1; metastasis; osteopontin; apoptosis; in vivo;
D O I
10.1002/ijc.23542
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer metastasis suppressor 1 (BRMS1) inhibits the ability of multiple human and murine cancer cell lines to metastasize to lymph nodes, bones and lungs. Comparison of mRNA expression in metastatic MDA-MB-435 human carcinoma cells (435) and metastasis-suppressed BRMS1 transfectants (435/BRMS1) showed a marked (>90%) reduction of osteopontin (OPN) mRNA and protein expression in BRMS1-overexpressing cells. OPN expression is associated with disease progression in patients, with higher levels of OPN produced by cancer cells associated with poorer patient survival. Furthermore, OPN has been suggested to promote survival of cancer cells in response to stress, although the mechanisms by which this may occur remain poorly understood. This study tested the hypothesis that re-expression of OPN in metastasis-suppressed 435/BRMS1 cells would reverse metastasis suppression and confer protection from stress-induced apoptosis. A stable pooled population of OPN overexpressing 435/BRMS1 cells was created (435/BRMS1/OPN). OPN re-expression did not affect in vitro cell growth rates; however, increased anchorage independent growth/survival and protection from hypoxia-induced apoptosis was observed (p < 0.05). In vivo, OPN re-expression in BRMS1 transfected cells did not affect in vivo primary tumor growth but did increase the incidence of spontaneous metastasis to lymph nodes and lungs in mice. These novel findings suggest that OPN downregulation by BRMS1 may be responsible, at least in part, for BRMS1-mediated metastasis suppression by sensitizing cancer cells to stress induced apoptosis. These studies clarify one mechanism by which BRMS1 can suppress metastasis. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:526 / 534
页数:9
相关论文
共 56 条
[1]  
Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
[2]  
Adwan H, 2004, INT J ONCOL, V24, P1235
[3]   Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer [J].
Allan, Alison L. ;
George, Rosamma ;
Vantyghem, Sharon A. ;
Lee, Mark W. ;
Hodgson, Nicole C. ;
Engel, C. Jay ;
Holliday, Ron L. ;
Girvan, David P. ;
Scott, Leslie A. ;
Postenka, Carl O. ;
Al-Katib, Waleed ;
Stitt, Larry W. ;
Uede, Toshimitsu ;
Chambers, Ann F. ;
Tuck, Alan B. .
AMERICAN JOURNAL OF PATHOLOGY, 2006, 169 (01) :233-246
[4]   Serial plasma osteopontin levels have prognostic value in metastatic breast cancer [J].
Bramwell, Vivien H. C. ;
Doig, Gordon S. ;
Tuck, Alan B. ;
Wilson, Sylvia M. ;
Tonkin, Katia S. ;
Tomiak, Anna ;
Perera, Francisco ;
Vandenberg, Theodore A. ;
Chambers, Ann F. .
CLINICAL CANCER RESEARCH, 2006, 12 (11) :3337-3343
[5]   Prognostic and predictive factors in breast cancer [J].
Bundred, NJ .
CANCER TREATMENT REVIEWS, 2001, 27 (03) :137-142
[6]  
Cameron MD, 2000, CANCER RES, V60, P2541
[7]  
CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO
[8]  
2-H
[9]   Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-κB activity [J].
Cicek, M ;
Fukuyama, R ;
Welch, DR ;
Sizemore, N ;
Casey, G .
CANCER RESEARCH, 2005, 65 (09) :3586-3595
[10]   Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis [J].
Cole, BF ;
Gelber, RD ;
Gelber, S ;
Coates, AS ;
Goldhirsch, A .
LANCET, 2001, 358 (9278) :277-286